Influence of immunosuppressive drugs on the recurrence of hepatocellular carcinoma after liver transplantation: A gap between basic science and clinical evidence

Transplantation

Volumn 91, Issue 11, 2011, Pages 1173-1176

  Schnitzbauer, Andreas A ^a   Schlitt, Hans J ^a   Geissler, Edward K ^a  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

Author keywords

CNI; Hepatocellular carcinoma; Immunosuppression; mTOR; Tumor recurrence

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; CYCLOSPORIN A; EVEROLIMUS; IMMUNOSUPPRESSIVE AGENT; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; STEROID; TACROLIMUS;

ANTINEOPLASTIC ACTIVITY; CANCER RECURRENCE; DISEASE FREE SURVIVAL; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG MEGADOSE; DRUG SUBSTITUTION; EVIDENCE BASED MEDICINE; HUMAN; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; LOW DRUG DOSE; NEPHROTOXICITY; OVERALL SURVIVAL; PANCREAS CANCER; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

CALCINEURIN; CARCINOMA, HEPATOCELLULAR; DISEASE-FREE SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; NEOPLASM RECURRENCE, LOCAL; TOR SERINE-THREONINE KINASES;

EID: 79958265328     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e318215e72b     Document Type: Review

References (23)

1. Kasiske BL, Snyder JJ, Gilbertson DT, et al. Cancer after kidney transplantation in the United States. Am J Transplant 2004; 4: 905.
2. Geissler EK, Schlitt HJ, Thomas G. mTOR, cancer and transplantation. Am J Transplant 2008; 8: 2212.
3. Guba M, von BP, Steinbauer M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: Involvement of vascular endothelial growth factor. Nat Med 2002; 8: 128.
4. Lang SA, Moser C, Fichnter-Feigl S, et al. Targeting heat-shock protein 90 improves efficacy of rapamycin in a model of hepatocellular carcinoma in mice. Hepatology 2009; 49: 523.
5. Ansell SM, Inwards DJ, Rowland KM Jr, et al. Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: A phase 2 trial in the North Central Cancer Treatment Group. Cancer 2008; 113: 508.
6. Galanis E, Buckner JC, Maurer MJ, et al. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: A North Central Cancer Treatment Group Study. J Clin Oncol 2005; 23: 5294.
7. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356: 2271.
8. Schnitzbauer AA, Zuelke C, Graeb C, et al. A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTORinhibitor- free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma. BMC Cancer 2010; 10: 190.
9. Decaens T, Roudot-Thoraval F, Bresson-Hadni S, et al. Role of immunosuppression and tumor differentiation in predicting recurrence after liver transplantation for hepatocellular carcinoma: A multicenter study of 412 patients. World J Gastroenterol 2006; 12: 7319.
10. Nocera A, Andorno E, Tagliamacco A, et al. Sirolimus therapy in liver transplant patients: An initial experience at a single center. Transplant Proc 2008; 40: 1950.
11. Vivarelli M, Bellusci R, Cucchetti A, et al. Low recurrence rate of hepatocellular carcinoma after liver transplantation: Better patient selection or lower immunosuppression? Transplantation 2002; 74: 1746.
12. Vivarelli M, Cucchetti A, Piscaglia F, et al. Analysis of risk factors for tumor recurrence after liver transplantation for hepatocellular carcinoma: Key role of immunosuppression. Liver Transpl 2005; 11: 497.
13. Zhou J, Fan J, Wang Z, et al. Conversion to sirolimus immunosuppression in liver transplantation recipients with hepatocellular carcinoma: Report of an initial experience. World J Gastroenterol 2006; 12: 3114.
14. Vivarelli M, Dazzi A, Cucchetti A, et al. Sirolimus in liver transplant recipients: A large single-center experience. Transplant Proc 2010; 42: 2579.
15. Chinnakotla S, Davis GL, Vasani S, et al. Impact of sirolimus on the recurrence of hepatocellular carcinoma after liver transplantation. Liver Transpl 2009; 15: 1834.
16. Vivarelli M, Cucchetti A, La BG, et al. Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: Reassessment of risk factors for tumor recurrence. Ann Surg 2008; 248: 857.
17. Vivarelli M, Dazzi A, Zanello M, et al. Effect of different immunosuppressive schedules on recurrence-free survival after liver transplantation for hepatocellular carcinoma. Transplantation 2010; 89: 227.
18. Zimmerman MA, Trotter JF, Wachs M, et al. Predictors of long-term outcome following liver transplantation for hepatocellular carcinoma: A single-center experience. Transpl Int 2007; 20: 747.
19. Zimmerman MA, Trotter JF, Wachs M, et al. Sirolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma. Liver Transpl 2008; 14: 633.
20. Kneteman NM, Oberholzer J, Al SM, et al. Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma. Liver Transpl 2004; 10: 1301.
21. Toso C, Meeberg GA, Bigam DL, et al. De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: Long-term outcomes and side effects. Transplantation 2007; 83: 1162.
22. Toso C, Merani S, Bigam DL, et al. Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma. Hepatology 2010; 51: 1237.
23. OCEBM Table of Evidence Working Group*. "The Oxford 2011 Table of Evidence". Oxford Centre for Evidence-Based Medicine. Available at: http://www.cebm.net/index.aspx?o-5653.